This trial will test whether the addition of bevacizumab to Optune improves meningioma control.
1 Primary · 3 Secondary · Reporting Duration: From time of registration to death, assessed up to 2 years
Experimental Treatment
27 Total Participants · 1 Treatment Group
Primary Treatment: Bevacizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: